Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Improving Atrial Fibrillation or Flutter Detection and Management by Smartphone-Based Photoplethysmography Rhythm Monitoring Following Cardiac Surgery: A Pragmatic Randomized Trial.
Europace
January 2025
Department of Cardiovascular Sciences, UZ Leuven, Leuven, Belgium.
Background And Aims: Atrial fibrillation (AF) or atrial flutter (AFL) after cardiac surgery are common and associated with adverse outcomes. The increased risk related to AF or AFL may extend beyond discharge. This study aims to determine whether photoplethysmography (PPG)-based smartphone monitoring to detect AF or AFL after hospital discharge following cardiac surgery improves AF management.
View Article and Find Full Text PDFCharacterizing Cardiac Adipose Tissue in Post-AMI Patients via CT Imaging: A Comparative Cross-sectional Study.
Eur Heart J Cardiovasc Imaging
January 2025
National Heart Center Singapore, Singapore, Singapore.
Aims: To identify differences in CT-derived perivascular (PVAT) and epicardial adipose tissue (EAT) characteristics that may indicate inflammatory status differences between post-treatment acute myocardial infarction (AMI) and stable coronary artery disease (CAD) patients.
Methods And Results: A cohort of 205 post-AMI patients (age 59.8±9.
Home intravenous diuretic administration for heart failure management: A scoping review.
PLoS One
January 2025
Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada.
Background: Heart failure (HF) significantly impacts healthcare systems due to high rates of hospital bed utilization and readmission rates. Chronic HF often leads to frequent hospitalizations due to recurrent exacerbations and a decline in patient health status. Intravenous (IV) diuretic administration is essential for treating worsening HF.
View Article and Find Full Text PDFTowards a broader perspective on non-alcoholic fatty liver disease and coronary artery disease relationship: managing metabolic risk beyond genetics.
Eur J Prev Cardiol
January 2025
Department of Clinical Sciences and Community Health, University of Milan, Via Commenda 19, Milan 20122, Italy.
SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health.
Kidney Med
August 2024
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Originally developed for use in type 2 diabetes mellitus (T2DM), sodium-glucose co-transporter-2 (SGLT2) inhibitors demonstrated diverse cardiovascular- and kidney-protective effects in large outcome trials. Their subsequent approval as a treatment for chronic kidney disease (CKD) marked a pivotal shift in the landscape of CKD management. Further to this, the approval of dapagliflozin and empagliflozin for use in patients with CKD with and without T2DM afforded new treatment opportunities for this population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!